CRISPR Gene Editing Used to Build 1st Model of AML Progression

CRISPR Gene Editing Used to Build 1st Model of AML Progression

287478

CRISPR Gene Editing Used to Build 1st Model of AML Progression

Blocking early inflammatory and innate immune signaling is a promising therapeutic target in acute myeloid leukemia (AML), as disruptions in these signaling pathways occur early and persist throughout the evolution of the disorder. This result comes from a recent study, in which researchers used CRISPR-Cas9 gene editing to observe how single healthy cells could become AML cancer cells, mapping the successive changes along the way. The study, “Sequential CRISPR gene editing in human iPSCs charts…

You must be logged in to read/download the full post.